Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 316 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hepatitis C Patients Clear all

Conditions: Hepatitis C, Chronic
Interventions: BI201335, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 6
States / cities: San Francisco, California • Baltimore, Maryland • New York, New York + 1 more

Conditions: Hepatitis C, Chronic
Interventions: Interleukin 28B testing; Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 4,766 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Alexandria, Virginia

Conditions: Hepatitis C, Chronic
Interventions: Telaprevir, Peg-IFN-alfa-2a, Ribavirin, Placebo; Drug
Lead sponsor: Tibotec BVBA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 663 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 31
States / cities: Birmingham, Alabama • Coronado, California • La Jolla, California + 28 more

Conditions: Chronic Hepatitis C Infection
Interventions: HCVax; Biological
Lead sponsor: GeneCure Biotechnologies; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hepatitis C
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV, Hepatitis C, Chronic
Interventions: Nurse Case Management; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hepatitis C, Chronic Kidney Disease
Interventions: Sofosbuvir/Ledipasvir FDC; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatitis C, Chronic
Interventions: PPI-668, Placebo; Drug
Lead sponsor: Presidio Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Costa Mesa, California • Sacramento, California • San Francisco, California + 1 more

Conditions: HIV Infections, Hepatitis C
Interventions: Ribavirin, Interferon alfa-2a, Peginterferon alfa-2a; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 24
States / cities: San Diego, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Chronic Hepatitis C, End Stage Renal Disease
Interventions: Ribavirin, Peginterferon, Boceprevir; Drug
Lead sponsor: Liver Institute of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hepatitis C
Interventions: Candesartan, Placebo; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 21 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Roseville, California • Sacramento, California

Conditions: Hepatitis C, Chronic
Interventions: Ribavirin, peginterferon alfa-2a [Pegasys]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 25
States / cities: Bakersfield, California • Pasadena, California • San Diego, California + 22 more

Conditions: Hepatitis C, Chronic
Interventions: Telaprevir, pegylated interferon (Peg-IFN) alfa-2a, ribavirin (RBV); Drug
Lead sponsor: Janssen Infectious Diseases BVBA; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 14
States / cities: Coronado, California • Los Angeles, California • San Francisco, California + 11 more

Conditions: Hepatitis C, Chronic, Nonadherence, Patient
Interventions: Digital Medicine; Device
Lead sponsor: Proteus Digital Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 253 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 16
States / cities: Birmingham, Alabama • San Francisco, California • Colorado Springs, Colorado + 12 more

Conditions: Hepatitis C, Medication Adherence
Interventions: Intensive Models (mDOT and CGT) of HCV Care; Other
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Chronic Hepatitis C
Interventions: Pegylated Interferon alfa-2b, Simeprevir, Ribavirin, Sofosbuvir; Drug
Lead sponsor: Center For Hepatitis C, Atlanta, GA; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hepatitis C, Chronic
Interventions: Copegus placebo, RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus], ritonavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 18
States / cities: La Jolla, California • Sacramento, California • Orlando, Florida + 14 more

Conditions: Hepatitis C, Hepatitis C, Chronic, HIV/AIDS
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hepatitis C, Chronic
Interventions: Copegus, Pegasys, boceprevir, mericitabine, mericitabine placebo, boceprevir placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 7
States / cities: Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more

Conditions: Hepatitis C Virus
Interventions: BMS-790052, Placebo, peginterferon alfa-2a, ribavirin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 35
States / cities: Montgomery, Alabama • La Jolla, California • Los Angeles, California + 28 more

Conditions: Hepatitis C
Interventions: MDX1106-02, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 7
States / cities: Anaheim, California • San Francisco, California • Springfield, Illinois + 4 more

Conditions: HIV Infections
Interventions: tipranavir, ritonavir; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 5
States / cities: Beverly Hills, California • Fort Lauderdale, Florida • Providence, Rhode Island + 2 more

Conditions: Hepatitis C Viral Infection, Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 4
Interventions: Faldaprevir, TD-6450, Ribavirin; Drug
Lead sponsor: Trek Therapeutics, PBC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Coronado, California

Conditions: Hepatitis C, Chronic
Interventions: Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 49
States / cities: Birmingham, Alabama • La Jolla, California • Long Beach, California + 41 more

Search by objective public record fields.

Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced

A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Therapeutic Hepatitis C Virus Vaccine

Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir.

Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection

Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)

A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1

A Comparison of the Effectiveness, Safety, and Tolerability of Two Different Hepatitis C Treatments in Patients Infected With Both HIV and Hepatitis C Virus (HCV)

A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)

Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin

VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence

Intensive Models of HCV Care for Injection Drug Users

The SIM-SOF Trial for Hepatitis C

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients

A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment

A Study of MDX-1106 to Treat Patients With Hepatitis C Infection

Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation

A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection

A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials